Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again

Dow Jones

2024-11-20

By Colin Kellaher

Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure.

Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading.

The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease.

Based on these results, the company does not plan further development of dalzanemdor.

Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 20, 2024 06:59 ET (11:59 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2484103192"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484103192\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484103192?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484103192","market":"other","top_or_hot":-1,"title":"Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n</p>\n<p>\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n</p>\n<p>\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n</p>\n<p>\n  Based on these results, the company does not plan further development of dalzanemdor. \n</p>\n<p>\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 06:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-20 19:59</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n</p>\n<p>\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n</p>\n<p>\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n</p>\n<p>\n  Based on these results, the company does not plan further development of dalzanemdor. \n</p>\n<p>\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 06:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2484103192","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484103192","pubTimestamp":1732103940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure.Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading.The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease.Based on these results, the company does not plan further development of dalzanemdor.Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SAGE":"Sage Therapeutics"},"translate_title":"Dalzanemdor再次失败后，Sage Therapeutics股价盘前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"By Colin Kellaher \n\n\n \n\n\nSage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n\n\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n\n\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n\n\n  Based on these results, the company does not plan further development of dalzanemdor. \n\n\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 06:59 ET (11:59 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}